Advertisement

IL-17 and Th17 cells in rheumatoid arthritis

  • Pierre Miossec
Part of the Progress in Inflammation Research book series (PIR)

Abstract

IL-17 was identified in 1995/96 as a T cell-derived cytokine with effects on inflammation and neutrophil activation. Rheumatoid arthritis has emerged as the most studied situation to justify the selection of IL-17 as a therapeutic target. By interacting with other proinflammatory cytokines, IL-17 was found to induce bone and cartilage destruction. In 2006, the precise cell source of IL-17 was identified in the mouse. These cells were named Th17 and their key role was demonstrated in various situations associated with inflammation and matrix destruction. These new findings confirmed and extended the results previously obtained following the identification of IL-17 as a T cell-derived cytokine. At the same time, additional information was obtained on the other members of the IL-17 family and on the structure of the IL-17 receptor complex. Such knowledge has further extended the choice of possible modalities to control IL-17.

Keywords

Rheumatoid Arthritis Th17 Cell Rheumatoid Arthritis Synovium Th17 Pathway Matrix Destruction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Miossec P (2003) Interleukin-17 in rheumatoid arthritis: If T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 48: 594–601PubMedCrossRefGoogle Scholar
  2. 2.
    Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S et al (1996) T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183: 2593–2603PubMedCrossRefGoogle Scholar
  3. 3.
    Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT et al (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103: 1345–1352PubMedCrossRefGoogle Scholar
  4. 4.
    Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P (1999) Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42: 963–970PubMedCrossRefGoogle Scholar
  5. 5.
    Zrioual S, Toh ML, Tournadre A, Zhou Y, Cazalis MA, Pachot A, Miossec V, Miossec P (2008) IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol 180: 655–663PubMedGoogle Scholar
  6. 6.
    Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, Cohen JI, Spriggs MK (1995) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3: 811–821PubMedCrossRefGoogle Scholar
  7. 7.
    Toy D, Kugler D, Wolfson M, Bos TV, Gurgel J, Derry J, Tocker J, Peschon J (2006) Cutting edge: Interleukin 17 signals through a heteromeric receptor complex. J Immunol 177: 36–39PubMedGoogle Scholar
  8. 8.
    Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, Park SH, Lee SH, Kim HY (2007) Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB-and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 46: 57–64CrossRefGoogle Scholar
  9. 9.
    Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54: 1122–1131PubMedCrossRefGoogle Scholar
  10. 10.
    Chabaud M, Fossiez F, Taupin JL, Miossec P (1998) Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161: 409–414PubMedGoogle Scholar
  11. 11.
    Chabaud M, Page G, Miossec P (2001) Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: Regulation by soluble receptors and Th2 cytokines. J Immunol 167: 6015–6020PubMedGoogle Scholar
  12. 12.
    Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T et al (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204: 2803–2812PubMedCrossRefGoogle Scholar
  13. 13.
    Hartupee J, Liu C, Novotny M, Li X, Hamilton T (2007) IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 179: 4135–4141PubMedGoogle Scholar
  14. 14.
    Attur MG, Patel RN, Abramson SB, Amin AR (1997) Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 40: 1050–1053PubMedCrossRefGoogle Scholar
  15. 15.
    Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, Filvaroff EH (2001) Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 16: 10–21PubMedCrossRefGoogle Scholar
  16. 16.
    Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H (2000) Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275: 768–775PubMedCrossRefGoogle Scholar
  17. 17.
    Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30: 340–346PubMedCrossRefGoogle Scholar
  18. 18.
    Van bezooijen RL, Farih-Sips HC, Papapoulos SE, Lowik CW (1999) Interleukin-17: A new bone acting cytokine in vitro. J Bone Miner Res 14: 1513–1521CrossRefGoogle Scholar
  19. 19.
    Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 3: 168–177PubMedCrossRefGoogle Scholar
  20. 20.
    Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y et al (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673–2682PubMedCrossRefGoogle Scholar
  21. 21.
    Page G, Miossec P (2005) RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 52: 2307–2312PubMedCrossRefGoogle Scholar
  22. 22.
    Harrington LE, Mangan PR, Weaver CT (2006) Expanding the effector CD4 T-cell repertoire: The Th17 lineage. Curr Opin Immunol 18: 349–356PubMedCrossRefGoogle Scholar
  23. 23.
    Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T et al (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744–748PubMedCrossRefGoogle Scholar
  24. 24.
    Page G, Sattler A, Kersten S, Thiel A, Radbruch A, Miossec P (2004) Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol 164: 409–417PubMedGoogle Scholar
  25. 25.
    Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P (2000) Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 12: 1092–1099PubMedCrossRefGoogle Scholar
  26. 26.
    Aarvak T, Chabaud M, Miossec P, Natvig JB (1999) IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162: 1246–1251PubMedGoogle Scholar
  27. 27.
    Chabaud M, Aarvak T, Garnero P, Natvig JB, Miossec P (2001) Potential contribution of IL-17-producing Th(1)cells to defective repair activity in joint inflammation: Partial correction with Th(2)-promoting conditions. Cytokine 13: 113–118PubMedCrossRefGoogle Scholar
  28. 28.
    Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F et al (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204: 1849–1861PubMedCrossRefGoogle Scholar
  29. 29.
    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238PubMedCrossRefGoogle Scholar
  30. 30.
    Chabaud M, Miossec P (2001) The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 44: 1293–1303PubMedCrossRefGoogle Scholar
  31. 31.
    Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356: 580–592PubMedCrossRefGoogle Scholar
  32. 32.
    Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, Blu menschein WM, McClanahan T, Brombacher F, Hurst SD et al (2007) IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 204: 161–170PubMedCrossRefGoogle Scholar
  33. 33.
    Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204: 33–39PubMedCrossRefGoogle Scholar
  34. 34.
    Miossec P (2007) Interleukin-17 in fashion, at last: Ten years after its description, its cellular source has been identified. Arthritis Rheum 56: 2111–2115PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2009

Authors and Affiliations

  • Pierre Miossec
    • 1
  1. 1.Department of Immunology and Rheumatology, Hôpital Edouard HerriotUniversity of LyonLyon Cedex 03France

Personalised recommendations